Clinical Data AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis BioSpaceUCB's Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie's Skyrizi in a Phase 3 head-to-head study of psoriatic arthritis.Immunology & InflammationRead full story pharminent May 20, 2026 (Last updated: May 21, 2026) BioSpace UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study of psoriatic arthritis. Immunology & Inflammation Read full story Post navigation Previous: GHO, CBC merge to create largest healthcare investment firmNext: Parabilis follows hefty Regeneron deal with IPO push Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026